OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more
OS Therapies Incorporated (OSTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.000x
Based on the latest financial reports, OS Therapies Incorporated (OSTX) has a cash flow conversion efficiency ratio of -1.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.71 Million) by net assets ($4.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OS Therapies Incorporated - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OS Therapies Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OS Therapies Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinxin Technology Holding Company American Depositary Shares
NASDAQ:NAMI
|
0.019x |
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
-0.119x |
|
Cementos Bio-B
SN:CEMENTOS
|
-0.003x |
|
Shougang Concord Century Holdings Limited
F:CW7
|
0.013x |
|
STEP Energy Services Ltd
PINK:SNVVF
|
0.058x |
|
BRISANET ON NM
SA:BRST3
|
0.061x |
|
INTRED S.P.A.
F:M7P
|
N/A |
|
Tasty Bite Eatables Limited
NSE:TASTYBITE
|
0.183x |
Annual Cash Flow Conversion Efficiency for OS Therapies Incorporated (2020–2024)
The table below shows the annual cash flow conversion efficiency of OS Therapies Incorporated from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $811.49K | $-7.28 Million | -8.974x | -7267.42% |
| 2023-12-31 | $-24.02 Million | $-3.01 Million | 0.125x | -42.04% |
| 2022-12-31 | $-17.56 Million | $-3.79 Million | 0.216x | -43.82% |
| 2021-12-31 | $-11.45 Million | $-4.40 Million | 0.384x | +0.81% |
| 2020-12-31 | $-6.33 Billion | $-2.41 Billion | 0.381x | -- |